Finance
Beta
search
Search or ask
settings
Theme
mobile
Device default
✓
dark_mode
Dark theme
light_mode
Light theme
Search labs
feedback
Send feedback
Sign in
Lists
playlist_add
New
4575
Research
4575:TYO
check_indeterminate_small
CanBas Co Ltd (Parent)
¥581.00
arrow_downward
-2.02%
(
-12.00
) 1D
Jun 2, 3:30:00 PM GMT+9 · JPY
area_chart
Area
stacked_line_chart
Compare
search
close
All symbols
monitoring
Indicators
No data
1D
5D
1M
6M
YTD
1Y
5Y
MAX
Symbol
Price
Change
% Change
Overview
Earnings
Financials
insights_auto
Generating top insights for 4575...
Open
¥571
High
¥583
Low
¥562
Mkt. cap
11.45B
Avg. vol.
142.85K
Volume
211.60K
52-wk high
¥1,558
52-wk low
¥562
EPS
-¥61
Shares outstanding
5.66M
No. of employees
14
Open
¥571
High
¥583
Low
¥562
Mkt. cap
11.45B
Avg. vol.
142.85K
Volume
211.60K
52-wk high
¥1,558
52-wk low
¥562
EPS
-¥61
Shares outstanding
5.66M
No. of employees
14
Related stocks
7776
CellSeed Inc
¥234.00
-2.50%
arrow_downward
4896
K Pharma Inc
¥688.00
-0.43%
arrow_downward
190A
Chordia Therapeutics Inc
¥103.00
0.00%
4565
Nxera Pharma Co Ltd
¥1,008.00
-0.79%
arrow_downward
News stories
From sources across the web
Yahoo Finance UK
·
38 minutes ago
Up 5.3%, the Dow Jones lags other US indices in 2026. Here’s why UK income investors should pay attention
Moomoo
·
42 minutes ago
May Wrap-Up, June Kickoff: Where Is the Money Actually Flowing?
www.marketscreener.com
·
41 minutes ago
Avanza trading volumes surge in May, modest gains for Nordnet - Nasdaq
Investor's Business Daily
·
6 hours ago
Dow Jones Futures: Broadcom, Micron, Nvidia, Sandisk Rally; Credo Plunges
Show more
About CanBas Co Ltd (Parent)
CEO
Takumi Kawabe M.D., Ph.D
Employees
14
Founded
Jan 18, 2000
Headquarters
Numazu, Shizuoka, Japan
Sector
Biotechnology
Website
canbas.co.jp
Previous reports
All values in JPY
Loading Previous Earnings...
Income statement
Balance sheet
Cash flow
Income statement
Revenue
Net income
calendar_month
Quarterly
Quarterly
Annual
All values in JPY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
239.00M
283.00M
162.00M
241.00M
Cost of revenue
239.00M
283.00M
162.00M
241.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
-23.00M
77.00M
78.00M
75.00M
Operating expense
72.00M
77.00M
78.00M
75.00M
Total operating expenses
311.00M
360.00M
240.00M
316.00M
Operating income
-311.00M
-360.00M
-240.00M
-316.00M
Other non operating income
-1.00M
1.00M
-
-
EBT including unusual items
-325.00M
-348.00M
-220.00M
-305.00M
EBT excluding unusual items
-325.00M
-348.00M
-220.00M
-305.00M
Income tax expense
1.00M
-
-
-
Effective tax rate
-0.31%
-
-
-
Other operating expenses
95.00M
-
-
-
Net income
-326.00M
-348.00M
-220.00M
-305.00M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
2.00M
-
2.00M
Interest expense
-
-
-
-
Net interest expenses
-
2.00M
-
2.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer
Research
edit_square
New thread
notes_spark
Thread history
close
Collapse
expand_content
Expand
add
Add Tool
travel_explore
Deep Search
arrow_upward
Ask AI
search_spark
AI content may include mistakes.
Learn more
Help
Send feedback
Privacy
Terms
Disclaimer